Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

Richard Gorlick, E. Anders Kolb, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernan Carol, Richard Lock, Doris Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine Billups, Malcolm A. Smith

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. Procedures: SCH 727965 was tested against the PPTP in vitro panel using 96hours exposure at concentrations ranging from 0.1nM to 1.0μM. It was tested against the PPTP in vivo panels at a dose of 40mg/kg administered intraperitoneally twice weekly for 2 weeks and repeated at Day 21 with a total observation period of 6 weeks. Results: The median IC50 value for the cell lines was 7.5nM, with less than fourfold range between the minimum (3.4nM) and maximum (11.2nM) IC50 values. SCH 727965 demonstrated an activity pattern consistent with cytotoxicity for most of the cell lines. Forty-three xenograft models were studied and SCH 727965 induced significant delays in event free survival distribution compared to control in 23 of 36 (64%) evaluable solid tumor xenografts and in 3 of 7 ALL xenografts. SCH 727965 did not induce objective responses in the solid tumor panels and the best response observed was stable disease for one osteosarcoma xenograft. In the leukemia panel, there were two objective responses with a complete response observed in a single xenograft. Conclusions: SCH 727965 shows an interesting pattern of activity suggesting its potential applicability against selected childhood cancers, particularly leukemias.

Original languageEnglish (US)
Pages (from-to)1266-1274
Number of pages9
JournalPediatric Blood and Cancer
Volume59
Issue number7
DOIs
StatePublished - Dec 15 2012

Fingerprint

CDC2 Protein Kinase
Heterografts
Pediatrics
Inhibitory Concentration 50
Leukemia
Cell Line
Neoplasms
Osteosarcoma
dinaciclib
Disease-Free Survival
Observation

Keywords

  • Developmental therapeutics
  • Dinaciclib
  • Preclinical testing
  • SCH 727965

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. / Gorlick, Richard; Kolb, E. Anders; Houghton, Peter J.; Morton, Christopher L.; Neale, Geoffrey; Keir, Stephen T.; Carol, Hernan; Lock, Richard; Phelps, Doris; Kang, Min H.; Reynolds, C. Patrick; Maris, John M.; Billups, Catherine; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 59, No. 7, 15.12.2012, p. 1266-1274.

Research output: Contribution to journalArticle

Gorlick, R, Kolb, EA, Houghton, PJ, Morton, CL, Neale, G, Keir, ST, Carol, H, Lock, R, Phelps, D, Kang, MH, Reynolds, CP, Maris, JM, Billups, C & Smith, MA 2012, 'Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, no. 7, pp. 1266-1274. https://doi.org/10.1002/pbc.24073
Gorlick, Richard ; Kolb, E. Anders ; Houghton, Peter J. ; Morton, Christopher L. ; Neale, Geoffrey ; Keir, Stephen T. ; Carol, Hernan ; Lock, Richard ; Phelps, Doris ; Kang, Min H. ; Reynolds, C. Patrick ; Maris, John M. ; Billups, Catherine ; Smith, Malcolm A. / Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 7. pp. 1266-1274.
@article{62326cb8b6fe45c2b342a74bef30543d,
title = "Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program",
abstract = "Background: SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. Procedures: SCH 727965 was tested against the PPTP in vitro panel using 96hours exposure at concentrations ranging from 0.1nM to 1.0μM. It was tested against the PPTP in vivo panels at a dose of 40mg/kg administered intraperitoneally twice weekly for 2 weeks and repeated at Day 21 with a total observation period of 6 weeks. Results: The median IC50 value for the cell lines was 7.5nM, with less than fourfold range between the minimum (3.4nM) and maximum (11.2nM) IC50 values. SCH 727965 demonstrated an activity pattern consistent with cytotoxicity for most of the cell lines. Forty-three xenograft models were studied and SCH 727965 induced significant delays in event free survival distribution compared to control in 23 of 36 (64{\%}) evaluable solid tumor xenografts and in 3 of 7 ALL xenografts. SCH 727965 did not induce objective responses in the solid tumor panels and the best response observed was stable disease for one osteosarcoma xenograft. In the leukemia panel, there were two objective responses with a complete response observed in a single xenograft. Conclusions: SCH 727965 shows an interesting pattern of activity suggesting its potential applicability against selected childhood cancers, particularly leukemias.",
keywords = "Developmental therapeutics, Dinaciclib, Preclinical testing, SCH 727965",
author = "Richard Gorlick and Kolb, {E. Anders} and Houghton, {Peter J.} and Morton, {Christopher L.} and Geoffrey Neale and Keir, {Stephen T.} and Hernan Carol and Richard Lock and Doris Phelps and Kang, {Min H.} and Reynolds, {C. Patrick} and Maris, {John M.} and Catherine Billups and Smith, {Malcolm A.}",
year = "2012",
month = "12",
day = "15",
doi = "10.1002/pbc.24073",
language = "English (US)",
volume = "59",
pages = "1266--1274",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Houghton, Peter J.

AU - Morton, Christopher L.

AU - Neale, Geoffrey

AU - Keir, Stephen T.

AU - Carol, Hernan

AU - Lock, Richard

AU - Phelps, Doris

AU - Kang, Min H.

AU - Reynolds, C. Patrick

AU - Maris, John M.

AU - Billups, Catherine

AU - Smith, Malcolm A.

PY - 2012/12/15

Y1 - 2012/12/15

N2 - Background: SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. Procedures: SCH 727965 was tested against the PPTP in vitro panel using 96hours exposure at concentrations ranging from 0.1nM to 1.0μM. It was tested against the PPTP in vivo panels at a dose of 40mg/kg administered intraperitoneally twice weekly for 2 weeks and repeated at Day 21 with a total observation period of 6 weeks. Results: The median IC50 value for the cell lines was 7.5nM, with less than fourfold range between the minimum (3.4nM) and maximum (11.2nM) IC50 values. SCH 727965 demonstrated an activity pattern consistent with cytotoxicity for most of the cell lines. Forty-three xenograft models were studied and SCH 727965 induced significant delays in event free survival distribution compared to control in 23 of 36 (64%) evaluable solid tumor xenografts and in 3 of 7 ALL xenografts. SCH 727965 did not induce objective responses in the solid tumor panels and the best response observed was stable disease for one osteosarcoma xenograft. In the leukemia panel, there were two objective responses with a complete response observed in a single xenograft. Conclusions: SCH 727965 shows an interesting pattern of activity suggesting its potential applicability against selected childhood cancers, particularly leukemias.

AB - Background: SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. Procedures: SCH 727965 was tested against the PPTP in vitro panel using 96hours exposure at concentrations ranging from 0.1nM to 1.0μM. It was tested against the PPTP in vivo panels at a dose of 40mg/kg administered intraperitoneally twice weekly for 2 weeks and repeated at Day 21 with a total observation period of 6 weeks. Results: The median IC50 value for the cell lines was 7.5nM, with less than fourfold range between the minimum (3.4nM) and maximum (11.2nM) IC50 values. SCH 727965 demonstrated an activity pattern consistent with cytotoxicity for most of the cell lines. Forty-three xenograft models were studied and SCH 727965 induced significant delays in event free survival distribution compared to control in 23 of 36 (64%) evaluable solid tumor xenografts and in 3 of 7 ALL xenografts. SCH 727965 did not induce objective responses in the solid tumor panels and the best response observed was stable disease for one osteosarcoma xenograft. In the leukemia panel, there were two objective responses with a complete response observed in a single xenograft. Conclusions: SCH 727965 shows an interesting pattern of activity suggesting its potential applicability against selected childhood cancers, particularly leukemias.

KW - Developmental therapeutics

KW - Dinaciclib

KW - Preclinical testing

KW - SCH 727965

UR - http://www.scopus.com/inward/record.url?scp=84863299833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863299833&partnerID=8YFLogxK

U2 - 10.1002/pbc.24073

DO - 10.1002/pbc.24073

M3 - Article

C2 - 22315240

AN - SCOPUS:84863299833

VL - 59

SP - 1266

EP - 1274

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -